Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
BACKGROUND: Imeglimin is a first-in-class novel oral antidiabetic marketed in Japan as TWYMEEG(®) to treat type 2 diabetes mellitus. Its mode of action is distinct from all other anti-hyperglycemic classes. OBJECTIVE: To assess the pharmacokinetic and safety profile of imeglimin in Caucasian and Jap...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427879/ https://www.ncbi.nlm.nih.gov/pubmed/35867199 http://dx.doi.org/10.1007/s40261-022-01181-3 |